D. Symmons, What is rheumatoid arthritis, Br Med Bull, vol.51, pp.243-248, 1995.

G. A. Schellekens, B. A. De-jong, F. H. Van-den-hoogen, L. B. Van-de-putte, and W. J. Van-venrooij, Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies, J Clin Invest, vol.101, pp.273-281, 1998.

W. J. Van-venrooij and G. J. Pruijn, Citrullination: a small change for a protein with great consequences for rheumatoid arthritis, Arthritis Res, vol.2, pp.249-251, 2000.

E. Girbal-neuhauser, J. J. Durieux, M. Arnaud, P. Dalbon, M. Sebbag et al., The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues, J Immunol, vol.162, pp.585-594, 1999.

G. A. Schellekens, H. Visser, B. A. De-jong, F. H. Van-den-hoogen, J. M. Hazes et al., The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide, Arthritis Rheum, vol.43, pp.155-163, 2000.

C. Masson-bessière, M. Sebbag, E. Girbal-neuhauser, L. Nogueira, C. Vincent et al., The major synovial targets of the rheumatoid arthritisspecific antifilaggrin autoantibodies are deiminated forms of the alphaand beta-chains of fibrin, J Immunol, vol.166, pp.4177-4184, 2001.

I. Auger, C. Roudier, S. Guis, N. Balandraud, and J. Roudier, HLA-DRB1*0404 is strongly associated with anticalpastatin antibodies in rheumatoid arthritis, Ann Rheum Dis, vol.66, pp.1588-1593, 2007.

I. Auger, N. Balandraud, J. Rak, N. Lambert, M. Martin et al., New autoantigens in rheumatoid arthritis (RA): screening 8268 protein arrays with sera from patients with RA, Ann Rheum Dis, vol.68, pp.591-594, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-02440912

T. M. Roberts, Cell biology: a signal chain of events, Nature, vol.360, pp.534-535, 1992.

C. M. Crews and R. L. Erikson, Extracellular signals and reversible protein phosphorylation: what to Mek of it all, Cell, vol.74, pp.215-217, 1993.

T. Thalhamer, M. A. Mcgrath, and M. M. Harnett, MAPKs and their relevance to arthritis and inflammation, Rheumatology (Oxford), vol.47, pp.409-414, 2008.

C. W. Reuter, A. D. Catling, T. Jelinek, and M. J. Weber, Biochemical analysis of MEK activation in NIH3T3 fibroblasts. Identification of B-Raf and other activators, J Biol Chem, vol.270, pp.7644-7655, 1995.

F. C. Arnett, S. M. Edworthy, D. A. Bloch, D. J. Mcshane, J. F. Fries et al., The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis, Arthritis Rheum, vol.31, pp.315-324, 1988.

M. H. Andersen, J. Fensterle, S. Ugurel, S. Reker, R. Houben et al., Immunogenicity of constitutively active V599E Braf, Cancer Res, vol.64, pp.5456-5460, 2004.

J. Fensterle, J. C. Becker, T. Potapenko, V. Heimbach, C. S. Vetter et al., B-Raf specific antibody responses in melanoma patients, BMC Cancer, vol.4, p.62, 2004.

I. Auger, M. Martin, N. Balandraud, and J. Roudier, Rheumatoid arthritis-specific autoantibodies to peptidyl arginine deiminase type 4 inhibit citrullination of fibrinogen, Arthritis Rheum, vol.62, pp.126-131, 2010.

C. Peyssonnaux and A. Eychène, The Raf/MEK/ERK pathway: new concepts of activation, Biology of the Cell, vol.93, pp.53-62, 2001.

M. Nishikawa, A. Myoui, T. Tomita, K. Takahi, A. Nampei et al., Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653, Arthritis Rheum, vol.48, pp.2670-2681, 2003.

A. Kotlyarov, A. Neininger, C. Schubert, R. Eckert, C. Birchmeier et al., MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis, Nat Cell Biol, vol.1, pp.94-97, 1999.

D. S. Brown, A. J. Belfield, G. R. Brown, D. Campbell, A. Foubister et al., A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis, Bioorg Med Chem Lett, vol.14, pp.5383-5387, 2004.

J. Saklatvala, The p38 MAP kinase pathway as a therapeutic target in inflammatory disease, Curr Opin Pharmacol, vol.4, pp.372-377, 2004.

N. Damjanov, R. S. Kauffman, and G. T. Spencer-green, Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies, Arthritis Rheum, vol.60, pp.1232-1241, 2009.

K. D. Morrison and R. E. Cutler, The complexity of Raf-1 regulation, Current Opinion in Cell Biology, vol.9, pp.174-179, 1997.

E. K. Mercer and C. A. Pritchard, Raf proteins and cancer: B-Raf is identified as a mutational target, Biochimica et Biophysica Acta, vol.1653, pp.25-40, 2003.

. Charpin, Submit your next manuscript to BioMed Central and take full advantage of: ? Convenient online submission ? Thorough peer review ? No space constraints or color figure charges ? Immediate publication on acceptance ? Inclusion in PubMed, CAS, Scopus and Google Scholar ? Research which is freely available for redistribution, Autoantibodies to BRAF, a new family of autoantibodies associated with rheumatoid arthritis, vol.12, p.194, 2010.

. Charpin, Arthritis Research & Therapy, vol.12, 2010.